Recursion to Present Research Data on November 3
The company will broadcast updates from the CGA-IGC meeting following its third-quarter financial results report.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize patient well-being in their drug development process?
Recursion plans to host a public webinar on November 3, 2026, at 8:00 AM ET to present updates from the CGA-IGC annual meeting. The event follows the company's scheduled release of third-quarter 2026 financial results on November 2, 2026.
Why it matters
The upcoming presentation and associated regulatory update for REC-4881 mark key checkpoints in Recursion's drug development pipeline. Investors and researchers are monitoring these updates for progress within the firm's AI-enabled discovery framework.
Recursion maintains an AI-driven drug discovery platform and anticipates a regulatory update for its clinical-stage candidate, REC-4881, by the end of 2026. This timeline follows the upcoming Q3 2026 financial results release scheduled for November 2.
The players
Recursion
A Salt Lake City-based biotechnology firm utilizing AI-powered platforms to map biology and discover new therapeutic drug candidates.
The details
The webinar will feature data presentations and patient panels broadcast via X, LinkedIn, and YouTube. These sessions aim to provide insights into the company's research progress discussed at the CGA-IGC annual meeting in Denver. REC-4881 represents a core asset currently moving through the regulatory evaluation process.
Timeline
November 2, 2026: Recursion releases third quarter 2026 financial results.
November 3, 2026: Webinar presentation from the CGA-IGC annual meeting begins at 8:00 AM ET.
End of 2026: Expected regulatory update for the REC-4881 drug candidate.
The Tech Race
The firm aligns its technical updates with the CGA-IGC annual meeting to maintain visibility among clinical research peers. This broadcast follows the broader industry trend of utilizing major conferences to synchronize company milestones with external scientific validation.
The public can access the company's latest clinical data and earnings information via a live broadcast on X, LinkedIn, and YouTube. Interested parties should prepare to view the stream on November 3, 2026, to receive the company's official commentary.
The takeaway
Recursion is prioritizing transparency regarding its REC-4881 pipeline progress during the CGA-IGC meeting sessions. Observers should track the company's announcements through the end of 2026 for the specific regulatory update regarding that asset.
What happens next
Recursion will release its third-quarter 2026 financial results on November 2, 2026, followed by the CGA-IGC presentation on November 3, 2026.
Further reading
Learn more about the latest developments in the sector on our Biotech page.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust pharmaceutical companies to prioritize patient well-being in their drug development process?
